Compare Natera Inc. Common Stock (NTRA) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while First Trust NASDAQ 100 Technology Index Fund trades at $303.09 (market cap $4.40B). The key difference: Natera Inc. Common Stock is far larger — about 13× First Trust NASDAQ 100 Technology Index Fund's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, First Trust NASDAQ 100 Technology Index Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| NTRA | QTEC | |
|---|---|---|
Market Cap | $57.03B | $4.40B |
Volume | 1,131,157 | 160,706 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $340.28 |
52-Week Low | $179.42 | $207.03 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $324.27, down 0.59% on the day. The technical outlook is bullish based on moving averages, with key support at $321 and resistance at $335. Recent analysis highlights its equal-weighted exposure to the technology sector and better liquidity compared to peers.
The ETF offers broad tech exposure but faces sector-specific volatility risks. Upside potential hinges on technology sector performance, while downside risks include macroeconomic pressures on growth stocks. Investor sentiment remains mixed with a neutral oscillator reading.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
